Literature DB >> 16713578

PIASxalpha differentially regulates the amplitudes of transcriptional responses following activation of the ERK and p38 MAPK pathways.

Shen-Hsi Yang1, Andrew D Sharrocks.   

Abstract

Activation of the MAP kinase pathways leads to changes in gene expression profiles through direct targeting of transcription factors and their coregulators. Here we identify PIASxalpha as a key regulator that determines the differential response of the transcription factor Elk-1 to the ERK and the stress-activated p38 MAP kinase pathways. While PIASxalpha functions as a coactivator to facilitate SUMO and HDAC-2 removal from Elk-1 in response to ERK pathway activation, PIASxalpha acts in the opposite manner to inhibit HDAC-2 and SUMO loss following stress-activated MAP kinase pathway signaling. Thus, PIASxalpha either enhances or dampens down the activation of Elk-1 target genes, depending on the pathway activated. p38 MAP kinase-mediated PIASxalpha phosphorylation allows it to switch between these two alternative modes of operation. Thus, PIASxalpha acts as a key signal integrator that permits different responses from the same transcription factor, depending on the signaling pathway that is activated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713578     DOI: 10.1016/j.molcel.2006.03.037

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  26 in total

Review 1.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

Review 2.  PIAS proteins: pleiotropic interactors associated with SUMO.

Authors:  Miia M Rytinki; Sanna Kaikkonen; Petri Pehkonen; Tiina Jääskeläinen; Jorma J Palvimo
Journal:  Cell Mol Life Sci       Date:  2009-06-13       Impact factor: 9.261

Review 3.  Mechanisms of specificity in neuronal activity-regulated gene transcription.

Authors:  Michelle R Lyons; Anne E West
Journal:  Prog Neurobiol       Date:  2011-05-18       Impact factor: 11.685

4.  p38 MAPK pathway-dependent SUMOylation of Elk-1 and phosphorylation of PIAS2 correlate with the downregulation of Elk-1 activity in heat-stressed HeLa cells.

Authors:  Daipayan Chowdhury; Ajeet Singh; Avinash Gupta; Rajkumar Tulsawani; Ramesh Chand Meena; Amitabha Chakrabarti
Journal:  Cell Stress Chaperones       Date:  2019-02-19       Impact factor: 3.667

Review 5.  Emerging roles of SUMO modification in arthritis.

Authors:  Dongyao Yan; Francesca J Davis; Andrew D Sharrocks; Hee-Jeong Im
Journal:  Gene       Date:  2010-07-11       Impact factor: 3.688

Review 6.  Post-translational modifications of the progesterone receptors.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  J Steroid Biochem Mol Biol       Date:  2013-12-12       Impact factor: 4.292

7.  GnRH induces the c-Fos gene via phosphorylation of SRF by the calcium/calmodulin kinase II pathway.

Authors:  Heather A Ely; Pamela L Mellon; Djurdjica Coss
Journal:  Mol Endocrinol       Date:  2011-02-03

8.  Rev7/MAD2B links c-Jun N-terminal protein kinase pathway signaling to activation of the transcription factor Elk-1.

Authors:  Lin Zhang; Shen-Hsi Yang; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2007-02-12       Impact factor: 4.272

9.  Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function.

Authors:  M Guy Roukens; Mariam Alloul-Ramdhani; Alfred C O Vertegaal; Zeinab Anvarian; Crina I A Balog; André M Deelder; Paul J Hensbergen; David A Baker
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

10.  SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

Authors:  Sanna Kaikkonen; Tiina Jääskeläinen; Ulla Karvonen; Miia M Rytinki; Harri Makkonen; Daniel Gioeli; Bryce M Paschal; Jorma J Palvimo
Journal:  Mol Endocrinol       Date:  2008-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.